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Abstract The transcription factor nuclear factor UB (NF-UB)
plays a pivotal role in immune and inflammatory responses.
Activation of NF-UB requires the activity of IKK, a kinase
complex that contains two catalytic subunits, IKKK and IKKL,
and a regulatory subunit IKKQ. To understand how IKK activity
is regulated, we searched for IKKQ-interacting proteins by the
yeast two-hybrid system. These screenings identified CSN3, a
component of the COP9 signalsome, as a protein specifically
interacting with IKKQ. Overexpression of CSN3 inhibits NF-UB
activation triggered by tumor necrosis factor (TNF), but not
interleukin-1 (IL-1). Moreover, overexpression of CSN3 also
inhibits NF-UB activation triggered by proteins involved in TNF
signaling, including TNF-R1, TRAF2, RIP, and NIK, but not by
TRAF6, a protein involved in IL-1 signaling. These data suggest
that CSN3 is a specific negative regulator of TNF- but not IL-1-
induced NF-UB activation pathways. ß 2001 Published by
Elsevier Science B.V. on behalf of the Federation of European
Biochemical Societies.
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1. Introduction
Nuclear factor-UB (NF-UB) proteins are inducible transcrip-
tion factors controlling the expression of various genes in-
volved in in£ammatory and immune responses [1^4]. Under
physiological conditions, NF-UB is normally sequestered in
the cytoplasm through its association with inhibitors called
IUB [1^4]. In response to various stimuli, such as the proin-
£ammatory cytokines tumor necrosis factor (TNF) and inter-
leukin-1 (IL-1), IUBs are degraded and NF-UB is released to
enter the nucleus [1^4]. The proteasome-mediated degradation
of IUBs is initiated by phosphorylation on their speci¢c serine
residues [5,6]. The kinase responsible for the site-speci¢c phos-
phorylation of IUBs is called IKK, a 900 kDa protein complex
consisting of IKKK, IKKL, and IKKQ/NEMO [7^13]. In this
complex, IKKK and IKKL are two homologous catalytic sub-
units which can directly phosphorylate IUBs, while IKKQ is a
non-enzymatic regulatory subunit [7^13].
IKKQ was ¢rst identi¢ed in a genetic screening experiment
for components required for lipopolysaccharide (LPS)-in-
duced NF-UB activation [13]. It was soon found that IKKQ
is a component of the IKK complex [11]. IKKQ-de¢cient cell
lines are unable to respond to NF-UB-activating signals, in-
cluding TNF, IL-1 and LPS, suggesting that IKKQ is required
for NF-UB activation triggered by these divergent stimuli [11^
14]. IKKQ contains one leucine-zipper motif at its C-terminus
and two coiled-coil regions at its N-terminus and intermediate
region [11]. A mutant lacking the C-terminal leucine-zipper
motif can inhibit TNF-induced NF-UB activation, suggesting
that the C-terminus of IKKQ is critically involved in NF-UB
activation [11].
To gain more insight into how IKK is activated, we per-
formed yeast two-hybrid screening for proteins interacting
with the C-terminal domain of IKKQ. These screenings iden-
ti¢ed CSN3, a component of the COP9 signalsome [15^18], as
a speci¢c IKKQ-interacting protein. Furthermore, our ¢ndings
suggest that CSN3 is a speci¢c inhibitor of TNF- but not
IL-1-induced NF-UB activation.
2. Materials and methods
2.1. Reagents and cell line
Recombinant human TNF and IL-1 (RpD Systems), the anti-Flag
(Sigma) and anti-hemagglutinin (HA) (Covance) monoclonal antibod-
ies were purchased from the indicated manufacturers. The human
embryonic kidney 293 cell line was a gift from Dr. Zhaodan Cao
(Tularik, Inc.), and was maintained in high glucose Dulbecco’s modi-
¢ed Eagle’s medium containing 10% fetal bovine serum.
2.2. Plasmids
To construct mammalian expression plasmids for IKKQ, its mu-
tants, and CSN3, the inserts were ampli¢ed by PCR from a mixture
of cDNA libraries (Clontech), and cloned into the pRK-Flag and
pRK-HA vectors [19,20]. Antisense CSN3 plasmid was constructed
by inserting the CSN3 full-length cDNA into pcDNA3.1(3) (Invitro-
gen) in reverse orientation.
The NF-UB luciferase reporter construct was a gift from Dr. Gary
Johnson (National Jewish Medical and Research Center). The mam-
malian expression plasmids pRK-myc-TNFR-1, pRK-HA-TRAF2,
pRK-HA-RIP, pRK-myc-NIK, p65, pRK-Flag-TRAF6 and crmA
were provided by Dr. David Goeddel (Tularik Inc.).
2.3. Yeast two-hybrid screenings
The cDNA encoding the leucine-zipper motif-containing C-terminal
domain of IKKQ (amino acids 297^419) was inserted in frame into the
Gal4 DNA-binding domain vector pGBT9 (Clontech). The human
leukocyte and B cell two-hybrid cDNA libraries were from Clontech.
The isolation of positive clones and subsequent two-hybrid interaction
analyses were carried out according to the MATCH maker two-hy-
brid system protocol (Clontech). The identities of the positive clones
were analyzed by sequencing.
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2.4. Luciferase reporter gene assays
293 cells (V2U105) were seeded on 6 well (35 mm) dishes. Cells
were transfected the following day by the standard calcium phosphate
precipitation method [21] with 0.5 Wg of NF-UB-luciferase reporter
construct and various amounts of testing plasmids. Within the same
experiment, each transfection was performed in triplicate, and where
necessary, enough empty control plasmid was added to keep each
transfection receiving the same amount of total DNA. To normalize
for transfection e⁄ciency and protein amount, 0.3 Wg of RSV-L-ga-
lactosidase plasmid was added to all transfections. Luciferase reporter
assays were performed using a luciferase assay kit (Pharmingen) and
following the manufacturer’s protocols. L-Galactosidase activity was
measured using the Galacto-Light chemiluminescent kit (Tropix Inc.).
Luciferase activities were normalized on the basis of L-galactosidase
expression levels. Data shown are averages and standard deviations
from one of the representative experiments in which each transfection
was performed in triplicate.
2.5. Immunoprecipitation and Western blot
293 cells (V3U106 per 100 mm dish) were transfected with the
indicated amounts of plasmids by the calcium phosphate method
[21]. Thirty-six hours after transfection, cells were collected by centri-
fugation and lysed in 0.5 ml of lysis bu¡er (50 mM Tris^HCl, pH 8.0,
150 mM NaCl, 0.1% NP-40, 1 mM EDTA, 10 Wg/ml aprotinin, 10 Wg/
ml leupeptin, 1 mM phenylmethylsulfonyl £uoride, 20 mM NaF,
2 mM sodium pyrophosphate, 2 mM Na3VO4) for 30 min. Cell lysates
were incubated with 1 Wg of anti-Flag or control mouse IgG and 25 Wl
of a 1:1 slurry of Gamma Bind-G plus Sepharose (Amersham Phar-
macia) at 4‡C for 3 h. The Sepharose beads were washed three times
with 1 ml of lysis bu¡er. The precipitates were analyzed by Western
blot with indicated antibodies.
3. Results
It has been suggested that the N-terminal coiled-coil do-
main of IKKQ interacts with IKKK and IKKL, while the C-
terminal leucine-zipper-containing domain may interact with
upstream components of the NF-UB activation pathways
[11,12]. To identify additional proteins that regulate IKK,
we performed yeast two-hybrid screenings for proteins inter-
acting with the C-terminal domain of IKKQ (amino acids 297^
419). Using IKKQ (amino acids 297^419) as bait, we screened
V1U107 clones from a human B cell cDNA library and a
human leukocyte cDNA library. Among 18 positive clones
obtained, two (one from each library) encode CSN3, a protein
originally identi¢ed as a component of the COP9 signaling
complex [15^18].
To determine whether full-length IKKQ interacts with full-
length CSN3 in mammalian cells, we constructed mammalian
expression plasmids for HA-tagged CSN3 and Flag-tagged
IKKQ. These plasmids were transfected into 293 cells. Co-im-
munoprecipitation and Western blot experiments indicate that
IKKQ can physically interact with CSN3 in mammalian cells
(Fig. 1).
We next determined whether CSN3 can activate NF-UB by
reporter gene assays. As shown in Fig. 2, overexpression of
CSN3 could not activate NF-UB. However, overexpression of
CSN3 signi¢cantly inhibited TNF-induced NF-UB activation.
In contrast, CSN3 did not a¡ect IL-1-induced NF-UB activa-
tion (Fig. 2).
We further examined the e¡ect of CSN3 de¢ciency on
TNF- and IL-1-induced NF-UB activation. To do this, we
made a CSN3 antisense construct and transiently transfected
it into 293 cells. Western blot experiments indicated that the
expressed antisense CSN3 mRNA could partially inhibit ex-
pression of CSN3 protein (Fig. 3A). Consistent with an inhib-
itory role of CSN3 in TNF-induced NF-UB activation, trans-
fection of the antisense CSN3 construct potentiated TNF-
induced NF-UB activation (Fig. 3B).
Previously, it has been shown that the signaling molecules
TRAF2 and RIP function upstream of IKK and are involved
in the TNF-R1- but not IL-1 receptor-mediated NF-UB acti-
vation pathway [22^25], whereas TRAF6 is involved in IL-1
Fig. 1. IKKQ interacts with CSN3 in mammalian cells. 293 cells
(V5U106) were cotransfected with pRK-Flag-IKKQ (6 Wg) and
pRK-HA-SGN3 (8 Wg). Twenty-four hours after transfection, cells
were lysed and immunoprecipitated with a monoclonal anti-Flag
antibody or control mouse IgG. The immunoprecipitates were ana-
lyzed by Western blot with anti-HA antibody.
Fig. 2. CSN3 inhibits TNF- but not IL-1-induced NF-UB activation.
293 cells (V2U105) were transfected with 0.3 Wg of NF-UB-lucifer-
ase reporter plasmid, 0.3 Wg of RSV-L-galactosidase plasmid and
1 Wg of pRK-Flag-CSN3. Sixteen hours after transfection, cells were
treated with 20 ng/ml of TNF, 10 ng/ml of IL-1, or left untreated
for 8 h. Luciferase activity was measured and normalized on the ba-
sis of L-galactosidase levels. Data shown are relative luciferase activ-
ity compared with the control transfection.
Fig. 3. Down-regulation of CSN3 potentiates TNF-induced NF-UB
activation. A: Down-regulation of CSN3 protein by CSN3 antisense
construct. 293 cells were transfected with 1 Wg of pRK-Flag-CSN3
plasmid together with 8 Wg of either empty control plasmid or
CSN3 antisense construct. Twenty-four hours after transfection, the
cells were lysed and Western blot was performed with anti-Flag
antibody. B: Potentiation of TNF-induced NF-UB activation by
CSN3 antisense construct. 293 cells (V2U105) were transfected
with 0.3 Wg of NF-UB-luciferase reporter plasmid, 0.3 Wg of RSV-L-
galactosidase plasmid and 1 Wg of indicated plasmids. Sixteen hours
after transfection, cells were treated with 20 ng/ml of TNF or left
untreated for 8 h. Luciferase activity was then measured and nor-
malized on the basis of L-galactosidase levels. Data shown are rela-
tive luciferase activity compared with the control transfection.
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receptor but not TNF-R1 signaling [24,25]. We found that
overexpression of CSN3 could inhibit TNF-R1-, TRAF2-,
RIP- and NIK-, but not TRAF6-induced NF-UB activation
(Fig. 4). Taken together, these data suggest that CSN3 can
speci¢cally inhibit TNF- but not IL-1-induced NF-UB activa-
tion.
4. Discussion
It has been shown that IKKQ is critically involved in acti-
vation of NF-UB. Using the yeast two-hybrid system, we have
identi¢ed CSN3 as a speci¢c IKKQ-interacting protein. Hu-
man CSN3 was originally identi¢ed as one of the eight sub-
units in a complex called JAB1 (Jun activation domain-bind-
ing protein) containing signalsome [15^18]. This signalsome
was subsequently shown to be identical with the human
COP9 complex [11,16]. The evolutionarily conserved COP9
complex was originally identi¢ed as a repressor of light-con-
trolled development in Arabidopsis thaliana [15^18]. The pu-
ri¢ed human COP9 is a 450 kDa complex that can phosphor-
ylate IUBK and p105 [16]. In addition, CSN3 is also observed
in two or three larger complexes with molecular masses of up
to approximately 1000 kDa in the lysates of mammalian cells
[16]. Since the IKK complex is approximately 900 kDa, which
is close to 1000 kDa, our ¢nding that IKKQ interacts with
CSN3 suggests the possibility that IKKQ and CSN3 exist in
the same signaling complex.
In vitro translation experiments have shown that IKKQ can
interact with IKKL but not with IKKK [11,13]. However,
IKK complexes in IKKL-de¢cient cells contain IKKK associ-
ated with IKKQ [26^28]. N-terminal deletion mutants of IKKQ
have suggested that the critical site of interaction with IKK is
con¢ned to residues 135^235 [11,12]. Consistent with this is
the observation that C-terminal deletion mutants of IKKQ
lacking the ¢nal 119 [11] or 154 [12] amino acids are able to
interact with IKK.
In addition to IKKK and IKKL, several other IKKQ-inter-
acting proteins have recently been reported. Among them one
group are viral proteins, such as adenoviral E3-14.7, [29],
equine herpesviral vCLAP [30] and HTLV-1 Tax [31]. Anoth-
er group are cellular proteins including RIP, A20 and CIK/
ActI [32,33]. It has been shown that all three viral proteins
bind to the C-terminal region of IKKQ [29^31], while the
cellular protein RIP, A20, and CIK/ActI bind to the inter-
mediate region (amino acids 95^218) of IKKQ [32,33]. Our
results suggest that CSN3 binds to the C-terminal leucine-
zipper-containing domain (amino acids 297^419) of IKKQ.
Previously, it has been speculated that the C-terminal domain
of IKKQ may be responsible for linking the IKK complex to
upstream components of the NF-UB activation pathways [11].
It is possible that inhibition of TNF-induced NF-UB activa-
tion may be due to competition of CSN3 with the upstream
signaling components for binding to IKKQ.
Our data suggest that CSN3 speci¢cally inhibits TNF- but
not IL-1-induced NF-UB activation. This is surprising because
it has been suggested that TNF- and IL-1-induced NF-UB
activation pathways converge at IKK [4]. Recently, it has
been shown by gene knock-out studies that A20, a protein
interacting with IKKQ, can also speci¢cally inhibit TNF- but
not IL-1-induced NF-UB activation [34]. The mechanisms re-
sponsible for the di¡erent e¡ects of CSN3 and A20 on TNF-
and IL-1-induced NF-UB activation are not clear at this point.
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